【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Top Companion Diagnostic Companies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Industry Survey
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Companion Diagnostics
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Advancements in Biomarker Discovery
2.5.2 Genomics
2.5.3 Pharmacogenomics
2.5.4 Genomic Biomarkers in Oncology
2.5.5 Proteomics
2.5.6 Metabolomics
2.6 Development of Companion Diagnostics
2.7 Regulations in the Companion Diagnostics Market
2.7.1 FDA’s Draft Guidance on Companion Diagnostics
2.7.1.1 Laboratory Developed Tests (LDT) – A New Direction
3. The World Companion Diagnostics Market, 2016-2026
3.1 The Global Companion Diagnostics Market, 2015
3.2 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.3 Companion Diagnostics: Increasing Market Share of the IVD Market
3.4 The Companion Diagnostics Market by Submarket, 2015
3.5 Theranostics: Fastest Growing Segment of the CDx Market
3.6 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2016-2026
3.7 Drivers
3.7.1 Stakeholders in the Companion Diagnostics Market
3.7.2 Regulatory Authorities
3.7.3 Payers
3.7.4 Partnerships
3.8 Restraints
3.8.1 Competitive Landscape
3.8.2 Testing Laboratories
3.8.3 Physicians and Patients
4. Leading US-Based Companion Diagnostic Companies, 2016
4.1 Abbott Laboratories, Inc.
4.1.1 Abbott Laboratories: Financial Overview
4.1.2 Companion Diagnostics Product Portfolio
4.1.2.1 Vysis ALK Break Apart FISH Probe Kit
4.1.2.2 PathVysion HER-2 DNA Probe Kit
4.1.3 Companion Diagnostics in Pipeline
4.1.4 Recent Activity and Collaborations
4.1.4.1 Collaboration with Merck
4.1.4.2 Collaborative Efforts with Idera
4.1.4.3 Collaboration with AstraZeneca
4.2 Myriad Genetics
4.2.1 Myriad Genetics: Financial Overview
4.2.2 Myriad Genetics: Companion Diagnostics Product Portfolio
4.2.2.1 myRisk Hereditary Cancer Test
4.2.2.2 BRACAnalysis®
4.2.2.3 CCP Assay
4.2.2.4 PREZEON™
4.2.3 Myriad Genetics: Companion Diagnostics Pipeline
4.2.3.1 HRD Assay
4.2.4 Myriad Genetics: Companion Diagnostics Collaborations:
4.2.4.1 Myriad/AstraZeneca: Premarket Approval Application
4.2.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
4.2.4.3 Myriad/ TESARO Companion Collaboration
4.2.4.4 Collaboration with AbbVie
4.2.4.5 Agilent/Bristol-Myers Squibb
4.3 Genomic Health
4.3.1 Genomic Health: Financial Overview
4.3.2 Genomic Health: Companion Diagnostics Product Portfolio
4.3.2.1 Oncotype Dx Portfolio
4.3.2.2 Oncotype SEQ
4.3.3 Genomic Health: Companion Diagnostics in Pipeline
4.3.3.1 RxPonder Trial
4.3.4 Genomic Health: Collaborations & Partnerships
4.3.4.1 Partnership with OncoMed
4.3.4.2 Genomic Health Partners with Epic Sciences
4.4 Thermo Fisher Scientific – Life Technologies
4.4.1 Thermo Fisher: Financial Overview
4.4.2 Thermo Fisher: Geographic Segmentation
4.4.3 Recent Collaborations and Acquisitions
4.4.3.1 Acquisition of Life Technologies
4.4.3.2 Acquisition of Prionics
4.4.3.3 Acquisition of Advanced Scientifics, Inc.
4.4.3.4 Acquisition of Alfa Aesar
4.4.3.5 Affymetrix: Thermo Fisher’s Next Target
4.4.3.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
4.4.3.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
4.4.3.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson: Financial Overview
4.5.2 Johnson & Johnson Division by Region
4.5.3 Johnson & Johnson: Companion Diagnostics Portfolio
4.5.3.1 Companion Diagnostics Center of Excellence
4.5.4 Johnson & Johnson: Companion Diagnostics Partnerships
4.5.4.1 Collaboration with Tianjin Medical University Cancer Institute and Hospital
4.5.4.2 Partnership with Massachusetts General Hospital
4.5.4.3 Partnership with Biocartis
4.6 Laboratory Corporation of America (LabCorp)
4.6.1 LabCorp: Financial Overview
4.6.2 LabCorp Companion Diagnostics Portfolio
4.6.3 Recent M&A Activity and Other Key Developments
4.6.3.1 Agreement with Medco Health Sciences
4.6.3.2 Non-Exclusive License Agreement with Merck
4.6.3.3 Acquisition of Monogram Biosciences
4.6.3.4 Acquisition of Genzyme Genetics
4.6.3.5 Partnership with ARCA Biopharma
4.7 Illumina
4.7.1 Illumina: Financial Overview
4.7.2 Illumina: Companion Diagnostics Product Portfolio
4.7.2.1 MiSeqDx™ System
4.7.3 Illumina: Recent Activity & Collaborations
4.7.3.1 AstraZeneca Partners with Illumina
4.7.3.2 bioMérieux Collaborates with Illumina
5. Leading European Companion Diagnostic Companies, 2016
5.1 Roche: Global Diagnostics Leader
5.1.1 Ventana Medical Systems (Roche)
5.1.2 Roche: Financial Overview
5.1.3 Roche Diagnostics Geographic Segmentation
5.1.4 Roche’s Collaborations and Recent Activity
5.1.5 Roche Diagnostics: Companion Diagnostics Product Portfolio & Pipeline
5.1.6 Ventana Companion Diagnostics: Robust New Prototype Assays
5.1.7 Recent Companion Diagnostic External Collaborations
5.1.7.1 Foundation Medicine and Roche Collaborate
5.1.7.2 Ventana Partners with Genmab
5.1.7.3 Ferring Collaborates with Roche for CDx Development for Infertility Treatment
5.1.7.4 MedImmune Partners with Ventana
5.1.7.5 Merck Enters Agreement with Ventana
5.1.7.6 AstraZeneca and Roche Partnership
5.1.7.7 Boehringer Ingelheim Collaborate with Roche
5.1.7.8 ImmunoGen Enter Agreement with Ventana
5.1.8 Roche Diagnostics: Major M&A Activity and Strategic Partnerships
5.1.8.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
5.1.8.2 IQuum Acquisition Allows Movement into POC MDx Market
5.1.8.3 Seragon Acquisition Strengthens Leading Position in Oncology
5.1.8.4 Santaris Acquisition Enhances Roche’s Position in RNA-Targeted Drugs Market
5.1.8.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
5.1.8.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
5.1.8.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
5.1.8.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
5.1.8.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
5.1.8.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
5.2 Qiagen
5.2.1 Qiagen: Financial Overview
5.2.2 Qiagen: Geographic Segmentation
5.2.2.1 Qiagen: Companion Diagnostics Collaborations
5.2.2.2 Collaboration with Eli Lilly
5.2.2.3 Collaboration with AstraZeneca
5.2.2.4 Collaboration with Astellas Pharma
5.2.2.5 Collaboration with Novartis
5.2.2.6 Collaboration with Array BioPharma
5.2.2.7 Collaboration with Protagen
5.3 Agilent Technologies (Dako)
5.3.1 Life Sciences and Diagnostics Business
5.3.2 Agilent Life Sciences and Diagnostics: Financial Overview
5.3.3 Agilent: Next Generation Sequencing Platforms
5.3.4 Recent Companion Diagnostic Collaborations
5.3.4.1 Merck and Aglient Cancer Collaborations
5.3.4.2 Pfizer and Aglient an Ongoing Collaboration
5.3.4.3 Bristol-Myers Squibb and Aglient Partnership
5.4 bioMérieux
5.4.1 bioMérieux: Financial Overview
5.4.2 Sales by Region, 2014
5.4.3 Sales by Technology, 2015
5.4.4 Companion Diagnostics: Recent M&A Activity & Collaboration
5.4.4.1 Collaboration with Gilead Sciences
5.4.4.2 Collaboration with Ipsen
5.4.4.3 Collaboration with Merck
5.4.4.4 Collaborations with GSK and Novartis
5.4.4.5 Mergers, Acquisitions and Collaborations
5.4.5 bioTheranostics: Subsidiary for Oncology Diagnostics
5.5 Siemens Healthcare
5.5.1 Siemens: Financial Overview
5.5.2 Siemens Healthcare
5.5.3 Siemens Diagnostics
5.5.4 Outperforming the Market
5.5.5 Companion Diagnostics
5.5.5.1 Partnership with Pfizer
5.5.5.2 Partnership with ViiV Healthcare
5.5.5.3 Partnership with Tocagen
5.6 MDxHealth
5.6.1 MDxHealth: Financial Overview
5.6.2 Companion Diagnostics
5.6.2.1 PharmacoMDx
5.6.2.2 PredictMDx for Brain Cancer
5.6.2.3 PredictMDx for Colon Cancer
5.6.3 R&D Capabilities
5.6.4 Recent Collaborations and Partnerships
5.6.4.1 Cerba HealthCare Belgium Collaboration
5.6.4.2 SouthGenetics Partnership
5.6.4.3 Sumitomo Sign Pharmaco Partnership for Japan
5.6.4.4 Partnership with GSK
6. Leading Rest of the World Companion Diagnostic Companies, 2016
6.1 MedGenome
6.1.1 MedGenome: Companion Diagnostics Product Portfolio
6.1.1.1 Integrated Genomics Platform
6.1.1.2 OncoPept
6.1.1.3 OncoMD
6.1.1.4 Next-Generation Sequencing Informatics
6.2 Diagnocure
6.2.1 Diagnocure Products
6.2.1.1 Gene Expression and Copy Number Variation (CNV) Analysis
6.2.1.2 Mutation Detection
6.2.1.3 SNP Genotyping
6.2.1.4 Platform and Laboratory Environment
6.2.2 DiagnoCure Collaborations and Partnerships
6.3 Seegene Inc.
6.3.1 Seegene: Product Portfolio
6.3.1.1 MuDT™(Multiple Detection Temperatures) Technology
6.3.1.2 TOCE™ Technology
6.3.1.3 DPO™ Technology
6.3.1.4 READ Technology
6.3.1.5 ACP™ Technology
6.3.2 Seegene Collaborations and Partnerships
6.4 Savyon Diagnostics
6.4.1 Savyon: Product Portfolio
6.4.1.1 NanoCHIP®
6.4.2 Savyon Diagnostics Product Lines
6.4.3 Savyon Diagnostics Services
6.5 Other Leading Companion Diagnostics Partnerships
7. Research Interview
7.1 Dr Ramprasad, Chief Operating Officer, and Mr Hiranjith G H, Director, Corporate Planning, MedGenome
7.1.1 MedGenome Overview
7.1.2 CDx Portfolio at MedGenome
7.1.3 MedGenome’s Competitive Advantage
7.1.4 Future Directions For MedGenome and the Industry
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market, 2016-2026
8.1.1 Strengths
8.1.1.1 A CDx Strategy Decreases the Length of Approval Process
8.1.1.2 Premium Prices for Companion Diagnostics
8.1.1.3 A CDx Development Strategy Can Generate More Effective Drugs
8.1.1.4 Therapeutics Tied with CDx can have Safer Profiles
8.1.1.5 Reducing the Cost of Healthcare
8.1.1.6 Increased Regulatory Scrutiny on Marketed Drugs
8.1.1.7 Targeted Therapies Will Drive the CDx Market
8.1.2 Weaknesses
8.1.2.1 Reimbursement Challenges
8.1.2.2 Lack of Clear Regulatory Guidelines
8.1.2.3 Capital Intensity is High
8.1.3 Opportunities
8.1.3.1 Fast-growing Emerging Markets
8.1.3.2 Next Generation Sequencing
8.1.3.3 Many New CDx/ Pharma Company Partnerships
8.1.4 Threats
8.1.4.1 Complex Business Models and Business Partnerships
8.1.4.2 Medical Device Excise Tax
8.2 STEP Analysis of the Companion Diagnostics Market, 2016-2026
8.2.1 Social Factor: Raising Awareness will Lead to Greater Product Adoption
8.2.2 Technologically Innovation Driven – Growing Manufacturing Efficiency
8.2.3 Economic Potential: Emerging Markets Create Demand
8.2.4 Political Issues: Government Influence
9. Conclusions from Our Research and Analysis
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
【レポート販売概要】
■ タイトル：医療機器リーダーシリーズ：コンパニオン診断薬（CDx）開発、製造および販売のトップ企業2016■ 英文：Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016
■ 発行日：2016年8月
■ 調査会社：visiongain
■ 商品コード：VGAIN60907
■ 調査対象地域：グローバル
- Efinaconazole (Dermatophytic Onychomycosis)：市場予測と分析（～2022）Efinaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Efinaconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022”. Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or n …
- 燃料用石油コークスの世界市場2019-2023About this market Application of fuel-grade petcoke in blast furnaces to drive market growth. Fuel-grade petcoke is an essential commercial product that is widely used in power generation, cement kilns, and other industries. Blast furnaces are widely used for manufacturing iron and steel. They consume a significant amount of energy. Coking coal is the dominant source of energy in blast furnaces. C …
- 暗視画像システム （NVIS）照明用LEDの世界市場This is the ElectroniCast forecast of global market consumption of packaged light emitting diodes (LEDs), also known as component-level bulbs, used in Night Vision Imaging System (NVIS) compatible lighting for non-civilian use, such as military, law enforcement, emergency medical services (EMS) and related. A night vision device (NVD) comprises of an Infrared (IR) image intensifier tube in a rigid …
- 世界のテレフタル酸ポリエチレン(PET)樹脂及びポリブチレンテレフタレート(PBT)樹脂市場PET & PBT are the main types of thermoplastic polyester resin market. The report covers the important PET resin markets by applications, such as bottles, films, food packaging, and others; and the PBT resin market, such as automotive, electrical & electronics, consumer appliances, and others. The market data for each application is given in terms of volume (thousand tons) and value ($million). The …
- セラミックファイバーの世界市場：RCF、多結晶繊維、生体内耐久性繊維About the Ceramic Fiber Market Ceramic fibers are popular in several end-user industries, including petrochemicals, iron and steel, ceramics, aluminum, and power generation because of their properties. These properties include: • Abrasion resistance • Low shrinkage • Thermal mechanical and insulation properties • Non-hygroscopic properties • Electrical properties Technavio’s analysts forecast the …
- 医療IT統合の世界市場予測：インターフェースエンジン、医療機器統合、メディア統合“The healthcare IT integration solutions market is projected to grow at a CAGR of 10.9%.”The global healthcare IT integration solutions market is projected to reach USD 5.3 billion by 2024 from USD 3.1 billion in 2019, at a CAGR of 10.9% during the forecast period. The market for HCIT integration solutions is primarily driven by the increasing need for integration owing to the rising healthcare co …
- 特殊テープの世界市場2019-2023About this market The construction industry is a major end-user of specialty tapes. Therefore, the growth in the global construction market is expected to drive the demand for specialty tapes for construction applications. The global housing market has been witnessing significant growth over the last three years, particularly in developed countries such as the US. The growth in the housing market …
- ペット食品成分の世界市場予測（～2025年）“The membrane filtration market is projected to grow at a CAGR of 6.6%.”The global pet food ingredients market is estimated to be valued at USD 37.0 billion in 2019 and is projected to reach USD 54.3 billion by 2025, at a CAGR of 6.6% from 2019 to 2025. The market is driven by factors such as the growing pet adoption rate among the urban population with a substantial improvement in pet food expend …
- 塗装装置の世界市場予測（～2021年）：液体塗装装置、粉末塗装装置、特殊塗装装置“The coating equipment market is projected to grow at a CAGR of 5.8% during the forecast period, 2016 to 2021.”The coating equipment market is projected to reach USD 19.33 billion by 2021, at a CAGR of 5.8% between 2016 and 2021. Growth of this market can be attributed to increasing requirements of customers for quick delivery of products, reduction in industrial maintenance time, and good finish. …
- IT運用分析の世界市場予測（～2022）：リアルタイムログ分析、アプリケーション性能管理The IT operations analytics (ITOA) market is projected to grow from an estimated USD 2.78 Billion in 2016 to USD 19.84 Billion by 2022, at a CAGR of 38.7% during the forecast period. Major growth drivers for this market include the tremendous growth of IT operations data and adoption of BYOD and IoT in organizations across industries. The solutions provided by various vendors in the ITOA market ar …
- 広告支出の世界市場2015-2019About Ad Spending Advertisement is a means of communication of an information about a product or service to a target audience. They are usually persuasive in nature and are mostly in a paid form. To target the audience, advertisements use every possible media that includes TV, print, Internet, radio, posters, events, visuals, and endorsements. To advertise a product or a service, a company hires a …
- スマート温室の世界市場：照明、気候制御、灌水システム、制御システムAbout Smart Greenhouse In a smart greenhouse, crops are cultivated under controlled conditions to optimize production. Technologies such as sensors and devices are used to automate the functions of the greenhouse. Smart greenhouses protect crops from diseases, pests, and harsh weather conditions, while at the same time consuming low amount of power and allowing remote access to the farmers. A smar …
- チェコの太陽光発電市場2016：発電能力、生産、投資動向、制度、企業Solar Photovoltaic (PV) in Czech Republic, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles Summary "Solar Photovoltaic (PV) in Czech Republic, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles” is the latest …
- 分子診断の世界市場予測（～2021年）The global molecular diagnostics market is projected to reach USD 10.12 billion by 2021 from USD 6.54 billion in 2016, at a CAGR of 9.1% from 2016 to 2021. High prevalence of infectious diseases and various types of cancer, increasing awareness and acceptance of personalized medicine and companion diagnostics, growth in the biomarker identification market and advancements in molecular techniques; …
- Cook Medical Incorporated：市場シェア分析Cook Medical Incorporated Market Share Analysis Summary GlobalData’s new report, “Cook Medical Incorporated Market Share Analysis” provides in-depth information on Cook Medical Incorporated ’s market position in the different medical equipment markets it operates in. The report provides Cook Medical Incorporated . market share information in two key market categories – Peripheral Vascular Devices …
